Shim J, Dean LE, Karabayas M, et al. - This study was sought to evaluate and predict the impact of anti-TNF therapy on axial spondyloarthritis (axSpA)-related fatigue. Across the UK, the British Society of Rheumatology Register in Axial Spondyloarthritis (BSRBR-AS) prospectively included axSpA individuals. Researchers compared variations in fatigue levels (measured using the Chalder Fatigue Scale) >1 year between those starting anti-TNF therapy at the time of recruitment and those not. Applying propensity score matching, variations between treatment groups were adjusted. Baseline predictors of response were evaluated among those BSRBR-AS anti-TNF commencers with clinically relevant fatigue. Amongst axSpA individuals, Anti-TNF therapy results in a significant but modest reduction in fatigue, with those reporting poor sleep quality most likely to report improvement. Additional approaches will be needed to effective management